The traditional clinical trials infrastructure may not be ideally suited to evaluate the numerous therapeutic hypotheses that result from the increasing number of available targeted agents combined with the various methodologies to molecularly subclassify patients with glioblastoma. Additionally, results from smaller screening studies are rarely translated to successful larger confirmatory studies, potentially related to a lack of efficient control arms or the use of unvalidated surrogate endpoints. Streamlining clinical trials and providing a flexible infrastructure for biomarker development is clearly needed for patients with glioblastoma. The experience developing and implementing the I-SPY studies in breast cancer may serve as a guide to developing such trials in neuro-oncology. © The Author(s) 2013. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
CITATION STYLE
Alexander, B. M., Wen, P. Y., Trippa, L., Reardon, D. A., Yung, W. K. A., Parmigiani, G., & Berry, D. A. (2013, August). Biomarker-based adaptive trials for patients with glioblastoma - Lessons from I-SPY 2. Neuro-Oncology. https://doi.org/10.1093/neuonc/not088
Mendeley helps you to discover research relevant for your work.